Table 2.

Percent reduction in HRSD score from baseline to end of treatment by genotype

SERT Genotype	Randomization group	Number of participants	N (%) in remission	Mean % reduction in HDRS	Std. Deviation	Std. Error Mean	T (df)	P-value (two tailed)
5-HTTLPR
l/l	Intervention	10	1 (10%)	−32.27	22.59	7.14	− .622 (19)	0.54
l/l	Control	11	1 (9%)	−25.70	25.46	7.68	− .622 (19)	0.54
s/l	Intervention	12	5 (42%)	−47.06	23.85	6.89	−2.53 (20)	0.02
s/l	Control	10	2 (20%)	−15.90	33.88	10.71	−2.53 (20)	0.02
s/s	Intervention	8	7 (85%)	−62.78	11.18	3.95	−3.8 (16)	0.002
s/s	Control	10	3 (30%)	−27.20	24.32	7.69	−3.8 (16)	0.002
STin2 VNTR
10/10	Intervention	5	1 (20%)	−22.49	30.20	13.51	−0.88 (4)	0.43
10/10	Control	1	0 (0%)	6.67	.	.	−0.88 (4)	0.43
9/10 or 10/12	Intervention	11	3 (27%)	−44.99	10.49	3.16	−2.2 (21)	0.37
9/10 or 10/12	Control	12	2 (16%)	−26.85	25.11	7.25	−2.2 (21)	0.37
9/12 or 12/12	Intervention	14	9 (64%)	−55.87	23.19	6.19	−3.5 (30)	0.001
9/12 or 12/12	Control	18	4 (22%)	−22.12	29.59	6.97	−3.5 (30)	0.001

Note: For each SERT polymorphism (5-HTTLPR and STin2 VNTR) the number of participants in intervention and control groups are shown. The middle columns give the number and percentage of these subjects in remission after 9 weeks (Hamilton Depression Rating Scale, HDRS, score of <10 as a surrogate for remission), the mean % reduction in their HDRS scores over the same time span, as well as standard deviation and standard error of the mean HDRS change over time. Results of the statistical analysis are shown to the right (df = degrees of freedom).